Sleeping Beauty: Anesthesia May Promote Relapse in Dogs With Diffuse Large B-Cell Lymphoma in Complete Remission After Chemo-Immunotherapy.
TIVA
anesthesia
dog
immunosuppression
isoflurane
lymphoma
propofol
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
08
2021
accepted:
28
10
2021
entrez:
9
12
2021
pubmed:
10
12
2021
medline:
10
12
2021
Statut:
epublish
Résumé
Surgery-induced stress and anesthesia-related immunosuppression are believed to play a critical role in human oncology patients. Studies have hypothesized that anesthesia influences patients' outcome, promoting tumor recurrence and metastasis. Aim of the study was to investigate whether anesthesia promoted relapse in dogs with diffuse large B-cell lymphoma (DLBCL). Medical records were searched for dogs with DLBCL, that were in complete remission (CR) after the same chemo-immunotherapy protocol. Dogs receiving anesthesia were included if the procedure was performed while in CR. Time to relapse (TTR) was obtained via Kaplan-Meier method. Association between anesthesia and relapse was assessed using a nested case-control design and estimated using conditional logistic regression. Sixty-one dogs with DLBCL were included. Overall median TTR was 329 days (95% CI, 281-377). Forty-eight (79%) dogs relapsed during the study period, while 13 (21%) were still in CR at data analysis closure. Eighteen (30%) dogs received anesthesia with opioids, propofol, and isoflurane or sevoflurane. The relative risk of lymphoma relapse for dogs undergoing anesthesia was significantly higher compared with dogs not undergoing anesthesia, with an odds ratio of 3.09 (
Identifiants
pubmed: 34881319
doi: 10.3389/fvets.2021.760603
pmc: PMC8645585
doi:
Types de publication
Journal Article
Langues
eng
Pagination
760603Informations de copyright
Copyright © 2021 Faroni, Sabattini, Lenzi, Guerra, Comazzi, Aresu, Mazzanti, Zanardi, Cola, Lotito and Marconato.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Manag Res. 2020 Feb 10;12:931-940
pubmed: 32104075
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
J Immunother Cancer. 2019 Jun 7;7(1):146
pubmed: 31174615
Front Vet Sci. 2016 Aug 31;3:77
pubmed: 27630997
Clin Cancer Res. 2014 Feb 1;20(3):668-77
pubmed: 24300788
Curr Ther Res Clin Exp. 2012 Feb;73(1-2):41-51
pubmed: 24653511
Vet J. 2013 Sep;197(3):776-81
pubmed: 23735731
Ups J Med Sci. 2014 Aug;119(3):251-61
pubmed: 24857018
J Vet Med Sci. 2013 Jul 31;75(7):917-21
pubmed: 23446140
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
J Anesth. 2011 Aug;25(4):569-75
pubmed: 21611862
Int J Cancer. 1977 Aug 15;20(2):213-8
pubmed: 892932
Anaesthesia. 2004 Oct;59(10):954-9
pubmed: 15488052
Epidemiology. 2011 Mar;22(2):228-31
pubmed: 21228697
Anesth Analg. 2003 Nov;97(5):1331-1339
pubmed: 14570648
Anesthesiology. 2016 Jan;124(1):69-79
pubmed: 26556730
Anesthesiology. 2012 Dec;117(6):1245-52
pubmed: 23090150
Korean J Anesthesiol. 2016 Apr;69(2):126-32
pubmed: 27066202
Vet Pathol. 2011 Jan;48(1):198-211
pubmed: 20861499
Immunopharmacol Immunotoxicol. 2007;29(3-4):477-86
pubmed: 18075859
J Vet Med Sci. 2015 Oct;77(10):1227-33
pubmed: 25960120
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Anesthesiology. 2005 Jun;102(6):1147-57
pubmed: 15915027
Nat Rev Clin Oncol. 2015 Apr;12(4):213-26
pubmed: 25601442